|
World Health Organization WHO
(2022)
C_WHO
|
|
|
Graham, S.M.et al.
International Union Against Tuberculosis and Lung Disease
(2016)
C1
|
|
|
Fernandes Maia, C.M.; Barbosa Martelli, D. R.; Mendes L. da Silveira, D. M.; et al.
Sociedade Brasileira de Pneumologia e Tisiologia
(2022)
CC
J Bras Pneumol. 2022;48(2):e20220082
The spread of Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2) continues to progress, causing damage in several countries of the world due to its rapid transmissibility and significant mortality rates, despite government measures to contain its transmission, such as movement control, the closing of schools, bans on travel and public gatherings, the mandatory use
of masks, and hand hygiene. The coronavirus disease (COVID-19) has clinical manifestations that are similar to those found in other infections also transmitted through the airways, such as pulmonary tuberculosis (TB) Although TB is a global health problem, it is a curable disease, with affordable treatment and prevention. Nonetheless, it remains one of the leading
causes of death from a single infectious agent worldwide, a situation threatened by COVID-19 ... more
|
|
|
Hussain.H.; Malik, A. A.
The Lancet
(2022)
CC
Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventive therapy is effective, safe, and feasible in a programme setting and what it will cost. For contact management and tuberculosis preventive therapy for multidrug-resistant and rifampicin-resistant tuberculosis, studies from high-income and low-income countries have shown feasibility, safety, and effectiveness.
However, there is scarce information on the cost of tuberculosis preventive therapy for multidrug-resistant and rifampicin-resistant tuberculosis. In The Lancet Global Health, Peter Dodd and colleagues show that household contact management strategies are cost-effective even in low-income and middle-income countries, which has important policy implications for achieving the END TB Strategy goals ... more
|
|
|
Bundesverbandes der Ärztinnen und Ärzte des Öffentlichen Gesundheitsdienstes (BVÖGD)
(2022)
C2
|
|
|
Reijer, P.; and S. Mauder
(2022)
CC
MEDBOX Issue Brief no. 19: World TB Day: Invest to end TB. Save Lives
|
|
|
Stop TB Partnership; WHO
(2022)
C_WHO
|
|
|
Turkova, A.; G.H. Wills, E. Wobudeya, et al.
(2022)
C2
|
|
|
World Health Organization WHO, Regional Office of Europe
(2022)
C_WHO
|
|
|
Robert Koch Institut
(2022)
C1
Epidemiologisches Bulletin ; 4/2022
|
|